PRX-07034 is a selective 5-HT₆ receptor antagonist. It has cognition and

memory Memory is the faculty of the mind by which data or information is encoded, stored, and retrieved when needed. It is the retention of information over time for the purpose of influencing future action. If past events could not be remembered ...

-enhancing properties and potently decreases

food intake Eating (also known as consuming) is the ingestion of food, typically to provide a heterotrophic organism with energy and to allow for growth. Animals and other heterotrophs must eat in order to survive — carnivores eat other animals, herbi ...

and body weight in rodents. PRX-07034 was under development by Epix Pharmaceuticals for the treatment of

obesity Obesity is a medical condition, sometimes considered a disease, in which excess body fat has accumulated to such an extent that it may negatively affect health. People are classified as obese when their body mass index (BMI)—a person's ...

and

cognitive impairment Cognitive deficit is an inclusive term to describe any characteristic that acts as a barrier to the cognition process. The term may describe * deficits in overall intelligence (as with intellectual disabilities), * specific and restricted defici ...

associated with Alzheimer's disease and

schizophrenia Schizophrenia is a mental disorder characterized by continuous or relapsing episodes of psychosis. Major symptoms include hallucinations (typically hearing voices), delusions, and disorganized thinking. Other symptoms include social wit ...

but upon the company collapsing due to lack of funds the compound was auctioned to another corporation.

References

External links

Preclinical Data on Predix Pharmaceuticals' 5-HT6 Antagonist for Obesity and Cognitive...

{{DEFAULTSORT:Prx-07034 Phenylpiperazines Anilines Phenol ethers Chloroarenes